Ultrasmall T1-T2 Magnetic Resonance Multimodal Imaging Nanoprobes for the Detection of β-amyloid Aggregates in Alzheimer's Disease Mice.
Jing CaiPeiwei YiYuqing MiaoJinbo LiuYaofang HuQicai LiuYanqiu FengHui-Xiong ChenLi LiPublished in: ACS applied materials & interfaces (2020)
Alzheimer's disease (AD) is an irreversible brain disorder and imposes a severe burden upon patients and the public health system. Most research efforts have focused on the search for effective therapeutic drugs, but it is time to pursue efficient early diagnosis based on the reasonable assumption that AD may be easier to prevent than reverse. Recent studies have shown that there are several probes for detecting amyloid-β (Aβ) plaques, one of the neuropathological hallmarks found in AD brain. However, it is still a great challenge for nonradioactive, sensitive detection and location of Aβ plaques by brain imaging with high spatial resolution. Herein, phenothiazine derivative (PZD)-conjugated sub-5 nm ultrasmall ferrite nanoprobes (UFNPs@PEG/PZD) are designed and prepared for efficient T1-T2 magnetic resonance multimodal imaging of Aβ plaques. UFNPs@PEG/PZD not only possess high binding affinity to Aβ plaques but also exhibit excellent properties of r1 and r2 relaxivities. This study thus provides a promising ultrasmall nanoplatform as an Aβ-targeting multimodal imaging probe for the application of early diagnosis of AD.
Keyphrases
- magnetic resonance
- high resolution
- fluorescence imaging
- sensitive detection
- photodynamic therapy
- resting state
- white matter
- end stage renal disease
- healthcare
- chronic kidney disease
- small molecule
- drug delivery
- pain management
- quantum dots
- type diabetes
- computed tomography
- functional connectivity
- cognitive decline
- mental health
- emergency department
- newly diagnosed
- risk factors
- multiple sclerosis
- early onset
- peritoneal dialysis
- adipose tissue
- transcription factor
- mild cognitive impairment
- quality improvement